Expert Ratings for Biomarin Pharmaceutical
Analysts provided the following ratings for Biomarin Pharmaceutical BMRN during the last quarter:
These 6 analysts have an average price target of $116.33 from Biomarin Pharmaceutical's current price of $89.52, implying upside.
Below is a summary of how these 6 analysts have rated Biomarin Pharmaceutical over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This average price target has increased by 3.87% over the past month.
Keep up to date with Biomarin Pharmaceutical's analyst ratings.
Analysts work in banking and financial systems and typically specialize in reporting on stocks or defined sectors. Analysts can attend company conference calls and meetings, research company financials, and communicate with insiders to issue "analyst notes" for stocks. Analysts typically rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and industry analysts are also human and only offer their opinions to investors.
If you want to track which analysts are outperforming others, you can view updated analyst ratings as well as analyst pass scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Analysts provided the following ratings for Biomarin Pharmaceutical BMRN during the last quarter:
These 6 analysts have an average price target of $116.33 from Biomarin Pharmaceutical's current price of $89.52, implying upside.
Below is a summary of how these 6 analysts have rated Biomarin Pharmaceutical over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This average price target has increased by 3.87% over the past month.
Keep up to date with Biomarin Pharmaceutical's analyst ratings.
Analysts work in banking and financial systems and typically specialize in reporting on stocks or defined sectors. Analysts can attend company conference calls and meetings, research company financials, and communicate with insiders to issue "analyst notes" for stocks. Analysts typically rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and industry analysts are also human and only offer their opinions to investors.
If you want to track which analysts are outperforming others, you can view updated analyst ratings as well as analyst pass scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?
